Motley Fool – Earnings Transcripts
Full earnings call transcripts from The Motley Fool
TOMI Environmental Solutions Inc (TOMZ) Q4 2025 Earnings Call Transcript
Thermo Fisher Scientific reported Q4 2025 revenue of $12.21 billion, a 7% year‑over‑year increase, and full‑year revenue of $44.56 billion, up 4%. Adjusted EPS rose 8% in the quarter to $6.57 and 5% for the year to $22.87, while adjusted operating margin held at 23.6% despite a 100‑basis‑point tariff and FX headwind. The company deployed $16.5 billion in capital, including $13 billion of acquisitions and a $9 billion definitive agreement to acquire Clario, expected to add roughly $0.45 of adjusted EPS in 2026. Guidance for 2026 projects 4‑6% revenue growth, 3‑4% organic growth, and 6‑8% adjusted EPS growth, with further upside from Clario’s integration.
GEN Restaurant Group Inc (GENK) Q4 2025 Earnings Call Transcript
Genco Shipping & Trading reported Q4 2025 adjusted EBITDA of $42 million, a 94% sequential rise and the highest quarterly level since 2022. Net income was $15.4 million and the board declared a $0.50 per share dividend, delivering a 9% annualized yield...
Faraday Future Intelligent Electric Inc (FFAI) Q4 2025 Earnings Call Transcript
Ford Motor Company reported $187 billion revenue for 2025, marking its fifth consecutive year of top‑line growth, and generated $6.8 billion adjusted EBIT after absorbing $2 billion each from Novelis fire losses and a tariff headwind. U.S. market share rose to 13.2%, the...
NextPlat Corp (NXPL) Q4 2025 Earnings Call Transcript
NextPlat Corp reported a 29% year‑over‑year revenue increase for the first half of fiscal 2025, marking its seventh straight double‑digit growth quarter. The company’s backlog surged to a record $4.5 billion, with 90% now expected to be realized over the next...
Direct Digital Holdings Inc (DRCT) Q4 2025 Earnings Call Transcript
Direct Digital Holdings (DRCT) posted Q4 2025 revenue of $206 million, up 8% year‑over‑year, and full‑year revenue of $748 million, up 14% YoY, delivering a 38% adjusted EBITDA margin for the quarter and 33% for the year. Growth was driven by a...
Lanzatech Global Inc (LNZA) Q4 2025 Earnings Call Transcript
Lazard Ltd. reported $3 billion in full‑year 2025 revenue, highlighted by a record $1.8 billion Financial Advisory haul and a 12% rise in assets under management to $261 billion. Q4 revenue reached $892 million, up 10% YoY, while Asset Management generated $339 million, an 18%...
ClearSign Technologies Corp (CLIR) Q4 2025 Earnings Call Transcript
ClearSign Technologies reported Q4 2025 results, with revenue climbing to $133,000 from $45,000 and net loss narrowing by roughly $200,000. Cash burn fell to $511,000, leaving $12.3 million in cash and equivalents. Management highlighted two cornerstone burner projects—a 20‑burner installation in...
Nexgel Inc (NXGL) Q4 2025 Earnings Call Transcript
Nexgel Inc. posted Q3 2025 revenue of $2.9 million, essentially flat year‑over‑year but modestly higher sequentially. Gross profit margin rose to 42.4% from 39.3% a year earlier, while adjusted EBITDA loss narrowed to $154 k. The company secured a $1 million non‑dilutive financing...
Omeros Corp (OMER) Q4 2025 Earnings Call Transcript
Omeros Corp reported a Q3 2025 net loss of $30.9 million, but secured a transformative agreement with Novo Nordisk that could deliver up to $2.1 billion in upfront and milestone payments. The $240 million upfront cash will retire most short‑term debt and fund more...
Venu Holding Corp (VENU) Q4 2025 Earnings Call Transcript
Garmin reported a record Q4 2025 with consolidated revenue of $2.13 billion, up 17% year‑over‑year, and full‑year revenue of $7.25 billion, a 15% increase. Operating margin expanded to 28.9% in the quarter, delivering $614 million of operating income and a pro‑forma EPS of...
Rekor Systems Inc (REKR) Q4 2025 Earnings Call Transcript
Rekor Systems posted a record $14.2 million Q4 revenue, up 35% year‑over‑year, and saw recurring revenue rise 18% to $6.5 million. Adjusted gross margin jumped to 63% from 44% a year earlier, while operating expenses fell 24% quarter‑over‑quarter, narrowing the adjusted EBITDA...
Galmed Pharmaceuticals Ltd (GLMD) Q4 2025 Earnings Call Transcript
MediWound reported a sharp Q4 revenue drop to $1.9 million, driven primarily by a U.S. government shutdown that delayed contract awards. R&D spending rose to $4.5 million as the company pushed the Phase III VALUE study for its EscharEx wound‑debridement therapy. A new...
JJill Inc (JILL) Q4 2026 Earnings Call Transcript
Genesco Inc. reported fiscal 2026 fourth‑quarter revenue of $800 million, a 7% year‑over‑year increase, with company‑wide comparable sales rising 9%. Journeys led growth, delivering 12% comparable sales and expanding its 4.0 store format to 84 locations, targeting a fleet share of...
Lithium Corp (LTUM) Q4 2025 Earnings Call Transcript
Lithia Motors reported record Q4 revenue of $9.2 billion, lifting full‑year sales to $37.6 billion, a 4% increase. Adjusted diluted EPS climbed 16% year‑over‑year to $33.46, driven by strong used‑vehicle and aftersales growth. Margin pressure persisted, with total vehicle GPU down $258...
Galectin Therapeutics Inc (GALT) Q4 2025 Earnings Call Transcript
Altimmune reported a strengthened cash position of roughly $340 million, extending its runway through 2028 to fund a pivotal Phase III NASH trial. The company disclosed that the trial will enroll about 1,800 patients globally, testing 1.8 mg and 2.4 mg doses of its...
Allurion Technologies Inc (ALUR) Q4 2025 Earnings Call Transcript
Allurion Technologies reported a record fourth‑quarter revenue of $1.05 billion, up 5.3% year‑over‑year, driven by a historic clear‑aligner volume of 677,000 cases. Non‑GAAP operating margin rose to 26.1%, while cash balances reached $1.09 billion. The Dental Service Organization (DSO) channel contributed roughly...
AEON Biopharma Inc (AEON) Q4 2025 Earnings Call Transcript
Abeona Therapeutics reported 2025 results highlighting the commercial launch of ZevaSkin, its first autologous cell‑based gene therapy for recessive dystrophic epidermolysis bullosa. Total revenue reached $5.8 million, driven by $2.4 million product sales and a $1.5 billion gain from selling a priority‑review voucher,...
Fermi Inc (FRMI) Q4 2025 Earnings Call Transcript
Ferroglobe reported Q4 2025 revenue of $329 million, up 6% sequentially, driven by a 13% rise in shipments of silicon‑based and manganese alloys. The company secured new trade safeguards in the EU and antidumping duties in the US, opening roughly 100,000‑110,000 tons...
Innventure Inc (INV) Q4 2025 Earnings Call Transcript
InvenTrust Properties Corp. reported a 5.3% same‑property NOI increase for 2025, driven by rent escalations, occupancy gains and strong leasing spreads. NAREIT FFO rose 6.2% to $1.89 per share and core FFO to $1.83, while the board lifted the annual...
DiaMedica Therapeutics Inc (DMAC) Q4 2025 Earnings Call Transcript
ADMA Biologics reported a robust 2025 year, posting $510.2 million in revenue—a 20% increase year‑over‑year—driven primarily by rapid growth of its specialty IVIG product Ascentive. Adjusted EBITDA rose 40% to $231 million and adjusted net income climbed 35% to $160.8 million, reflecting strong...
Spruce Power Holding Corp (SPRU) Q4 2025 Earnings Call Transcript
Spruce Power Holding Corp reported a GAAP net loss of $14.4 million for Q4 2025, but generated adjusted distributable earnings of $19.3 million, or $0.15 per share. The loan portfolio expanded 13% to $2.7 billion, driven by 32 new loans and a record‑high $416 million...
Sensei Biotherapeutics Inc (SNSE) Q4 2025 Earnings Call Transcript
Senseonics reported full‑year 2025 revenue of $35.3 million, a 60 % YoY increase, and lifted gross margin above 50 % after moving commercial operations in‑house. Q4 net revenue reached $14.3 million, while net loss narrowed to $20.8 million despite higher operating costs. The company secured...
VerifyMe Inc (VRME) Q4 2025 Earnings Call Transcript
VerifyMe Inc. reported Q2 2025 revenue of $4.5 million, a 17% decline year‑over‑year, while gross margin fell to 35% from 39%. Operating expenses were trimmed by 27%, driving adjusted EBITDA up to $300 k and narrowing the net loss to $290 k. Cash...
Actinium Pharmaceuticals Inc (ATNM) Q4 2025 Earnings Call Transcript
Actinium Pharmaceuticals reported adjusted 2025 revenue of $1.08 billion, a 14% increase year‑over‑year, driven by strong performance of its two core brands. NUPLAZID generated $692 million in adjusted net sales, up 15%, while DAYBUE posted $391 million, up 12%, aided by a 30%...
PDS Biotechnology Corp (PDSB) Q4 2025 Earnings Call Transcript
Palmer Square Capital BDC reported Q4 2025 results on Feb. 26, 2026, showing total investment income of $29.8 million, a 14.5% decline year‑over‑year, and net investment income of $13.1 million ($0.41 per share). The company paid a $0.43 per‑share dividend, including a...
DeFi Development Corp (DFDV) Q4 2025 Earnings Call Transcript
Definium Therapeutics reported that its lead psychedelic candidate DT120 ODT is on track for three pivotal Phase III readouts in 2026. The EMERGE MDD study is fully enrolled with top‑line data expected in late Q2, while the VOYAGE GAD trial...
Akari Therapeutics PLC (AKTX) Q4 2025 Earnings Call Transcript
Heron Therapeutics reported full‑year 2025 net product sales of $155 million and adjusted EBITDA of $14.7 million, surpassing its guidance and delivering a 73% gross margin. Acute Care drove the growth, with ZYNRELEF revenue up 48% YoY and APONVIE up 97%, resulting...
Range Impact Inc (RNGE) Q4 2025 Earnings Call Transcript
Ranger Energy Services reported Q4 2025 revenue of $142.2 million, essentially flat year‑over‑year but up sequentially, and generated adjusted EBITDA of $20.3 million, a 14.3% margin that improved from the prior quarter. The company highlighted two strategic pillars: the integration of the...
Progress Software Corp (PRGS) Q1 2026 Earnings Call Transcript
Progress Software reported fiscal 2025 revenue of $978 million, a 30% year‑over‑year increase, driven largely by the full‑year contribution of its ShareFile acquisition. Earnings per share rose 16% to $5.72, and the fourth‑quarter operating margin hit 38%, surpassing guidance. ARR reached...
Global Arena Holding Inc (GAHC) Q3 2025 Earnings Call Transcript
Gaia reported Q3 2025 revenue of $25 million, a 14 % year‑over‑year increase that lifts its annualized run rate to $100 million. Gross margin rose to 86.4 % and free cash flow turned positive at $0.9 million, while cash balances more than tripled to $14.2 million...
Pasithea Therapeutics Corp (KTTA) Q4 2025 Earnings Call Transcript
Kyntra Bio (formerly FibroGen) reported Q4 2025 results, highlighting a $109.4 million cash position and a debt‑free balance after selling its China assets to AstraZeneca, extending its runway to 2028. The company is advancing its CD46‑targeted ADC FG3246 and companion PET...
Unicycive Therapeutics Inc (UNCY) Q4 2025 Earnings Call Transcript
Unicycive Therapeutics reported a 40% revenue drop to $16.1 million for 2025, primarily from lost collaboration and contract manufacturing income, while license revenue modestly rose. R&D spending slipped slightly to $140.7 million, but SG&A surged $12.8 million as the company ramps up...
Terns Pharmaceuticals Inc (TERN) Q4 2025 Earnings Call Transcript
Geron Corporation reported full‑year 2025 Rytelo net revenue of $184 million and projected 2026 revenue between $220 million and $240 million, driven by sequential demand growth and a focus on the estimated 8,000 second‑line lower‑risk MDS patients in the U.S. Q4 demand rose...
Guided Therapeutics Inc (GTHP) Q4 2025 Earnings Call Transcript
G1 Therapeutics announced FDA approval of COSELA, a first‑in‑class therapy that reduces chemotherapy‑induced myelosuppression in extensive‑stage small cell lung cancer. The company began commercial launch in early February 2021, reporting rising physician awareness and positive payer feedback. It also outlined...
Phreesia Inc (PHR) Q4 2026 Earnings Call Transcript
Phreesia reported Q4 FY2026 revenue of $117.3 million, up 15% YoY, and posted its first GAAP net‑income positive quarter at $0.7 million. The company announced a definitive agreement to acquire AccessOne for $160 million in cash, a deal expected to add $35 million of...
Terrestrial Energy Inc (IMSR) Q4 2025 Earnings Call Transcript
Terex Corp completed its merger with REV Group, creating a standalone specialty vehicles segment and targeting $75 million of annual run‑rate synergies, half of which are expected within the next twelve months. The company delivered 2025 earnings per share of...
Nakamoto Inc (NAKA) Q4 2025 Earnings Call Transcript
Nasdaq (NASDAQ) reported full‑year 2025 net revenue of $5.2 billion, up 12% YoY, with solutions revenue surpassing $4 billion. Operating income rose 16% to $2.9 billion, delivering a 56% operating margin and a 24% increase in diluted EPS. The company achieved record index...
Boston Omaha Corp (BOC) Q4 2025 Earnings Call Transcript
Boston Omaha Corp reported $38 million revenue for the first nine months of 2025, a 28% year‑over‑year increase, driven by record performance and strong international demand, especially in India. Net income rose 54% to $2.8 million, reflecting profit leverage as the defense‑focused...
CBAK Energy Technology Inc (CBAT) Q4 2025 Earnings Call Transcript
CBAT’s Q4 2025 earnings call outlined a flat‑production outlook for 2026 while front‑loading 60% of its annual capital expenditures into the first half of the year, preserving flexibility to accelerate drilling if market conditions improve. The company highlighted its Deep...
Hirequest Inc (HQI) Q4 2025 Earnings Call Transcript
HireQuest reported a 9.8% year‑over‑year revenue decline to $8.5 million for Q3 2025, yet posted $2.3 million net income, reversing a loss from the prior year. Adjusted EBITDA margin expanded to 55% and workers’‑comp expenses fell dramatically, while core SG&A remained flat. System‑wide...
INmune Bio Inc (INMB) Q4 2025 Earnings Call Transcript
INmune Bio announced the first patient dosing in its phase‑2 XPro trial targeting neuroinflammation‑driven Alzheimer’s disease and outlined parallel phase‑2 studies in mild AD and MCI that leverage biomarker‑guided endpoints. The company also detailed a six‑week phase‑2 trial for treatment‑resistant...
USA Rare Earth Inc (USAR) Q4 2025 Earnings Call Transcript
Ultragenyx Pharmaceutical reported 2025 revenue of $673 million, a 20% year‑over‑year increase that topped the upper end of guidance. The company announced a 10% workforce reduction to streamline costs and focus on near‑term value drivers. Pipeline highlights include resubmission of...
Lexeo Therapeutics Inc (LXEO) Q4 2025 Earnings Call Transcript
Exelixis reported record cabozantinib franchise revenue of $2.12 billion in the U.S. and $2.89 billion globally for 2025, a 17% year‑over‑year increase. Total Q4 2025 revenue reached $599 million, driven by $546.6 million from cabozantinib net product sales and $52.8 million in partner royalties. The...
Lantern Pharma Inc (LTRN) Q4 2025 Earnings Call Transcript
nLIGHT Inc. reported a record full‑year 2025 revenue of $261 million, a 32% increase year‑over‑year, driven by a 60% surge in its aerospace and defense (A&D) segment to $175 million. The company posted an all‑time quarterly revenue of $81.2 million in Q4, with...
CXApp Inc (CXAI) Q4 2025 Earnings Call Transcript
CXApp Inc. reported Q4 2025 revenue of $1.1 million, down as the company deliberately phased out hardware sales, while gross margin climbed to 89% thanks to tighter cloud cost management. Operating expenses fell 8% to $4.8 million, narrowing the net loss to...
Bicara Therapeutics Inc (BCAX) Q4 2025 Earnings Call Transcript
Bausch Health Companies reported Q4 2025 revenue of $1.4 billion, a 9% year‑over‑year increase, and adjusted EBITDA of $773 million, up 9% and ahead of guidance. Full‑year results showed 7% reported revenue growth and double‑digit adjusted EBITDA expansion without major acquisitions. The...
Oxbridge Re Holdings Ltd (OXBR) Q4 2025 Earnings Call Transcript
Corebridge Financial reported a strong fourth‑quarter 2025, posting adjusted pretax operating income of $760 million and operating EPS of $1.22, a 15% year‑over‑year increase. Total sales reached a record $42 billion, up 4%, while the company returned $2.6 billion to shareholders, lifting the...
Airjoule Technologies Corp (AIRJ) Q4 2025 Earnings Call Transcript
Airgain Technologies reported Q4 2025 revenue of $12.1 million, matching the low end of its guidance, while full‑year revenue fell 15% to $51.8 million. The company improved its non‑GAAP gross margin to 46.3% and kept operating expenses flat, but posted a negative...
RenovoRx Inc (RNXT) Q4 2025 Earnings Call Transcript
RenovoRx reported Q4 2025 revenue of $266,000, bringing year‑to‑date sales to roughly $900,000 as it expands the RenovoCath platform across 14 approved cancer centers, up from five earlier in the year. The company ended the quarter with over $10 million in...
Fathom Holdings Inc (FTHM) Q4 2025 Earnings Call Transcript
Latham Group reported Q4 2025 net sales of $100 million, a 15% year‑over‑year increase, and full‑year revenue of $546 million, up 7%. The company saw strong growth in fiberglass pools, which now represent 76.5% of in‑ground sales and captured roughly 24% of...